ES2759725T3 - Esteroides 6-alquil-7-hidroxi-4-en-3-ona como intermediarios para la producción de moduladores de FXR esteroideo - Google Patents

Esteroides 6-alquil-7-hidroxi-4-en-3-ona como intermediarios para la producción de moduladores de FXR esteroideo Download PDF

Info

Publication number
ES2759725T3
ES2759725T3 ES15800909T ES15800909T ES2759725T3 ES 2759725 T3 ES2759725 T3 ES 2759725T3 ES 15800909 T ES15800909 T ES 15800909T ES 15800909 T ES15800909 T ES 15800909T ES 2759725 T3 ES2759725 T3 ES 2759725T3
Authority
ES
Spain
Prior art keywords
general formula
compound
alkyl
halo
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15800909T
Other languages
English (en)
Spanish (es)
Inventor
Alexander Weymouth-Wilson
Zofia Komsta
James Boydell
Carl Otter
Laura Wallis
Rhys Batchelor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nzp Uk Ltd
Original Assignee
Nzp Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1420594.2A external-priority patent/GB201420594D0/en
Priority claimed from GBGB1420593.4A external-priority patent/GB201420593D0/en
Priority claimed from GBGB1505670.8A external-priority patent/GB201505670D0/en
Application filed by Nzp Uk Ltd filed Critical Nzp Uk Ltd
Application granted granted Critical
Publication of ES2759725T3 publication Critical patent/ES2759725T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES15800909T 2014-11-19 2015-11-19 Esteroides 6-alquil-7-hidroxi-4-en-3-ona como intermediarios para la producción de moduladores de FXR esteroideo Active ES2759725T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1420594.2A GB201420594D0 (en) 2014-11-19 2014-11-19 Compounds
GBGB1420593.4A GB201420593D0 (en) 2014-11-19 2014-11-19 Compounds
GBGB1505670.8A GB201505670D0 (en) 2015-04-01 2015-04-01 Compounds
PCT/GB2015/053516 WO2016079517A1 (en) 2014-11-19 2015-11-19 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators

Publications (1)

Publication Number Publication Date
ES2759725T3 true ES2759725T3 (es) 2020-05-12

Family

ID=54704019

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15800909T Active ES2759725T3 (es) 2014-11-19 2015-11-19 Esteroides 6-alquil-7-hidroxi-4-en-3-ona como intermediarios para la producción de moduladores de FXR esteroideo

Country Status (15)

Country Link
US (1) US10301350B2 (cg-RX-API-DMAC7.html)
EP (1) EP3221331B1 (cg-RX-API-DMAC7.html)
JP (1) JP6700274B2 (cg-RX-API-DMAC7.html)
KR (1) KR102526631B1 (cg-RX-API-DMAC7.html)
CN (1) CN107207559B (cg-RX-API-DMAC7.html)
BR (1) BR112017010319B1 (cg-RX-API-DMAC7.html)
CA (1) CA2968309A1 (cg-RX-API-DMAC7.html)
DK (1) DK3221331T3 (cg-RX-API-DMAC7.html)
EA (1) EA033427B1 (cg-RX-API-DMAC7.html)
ES (1) ES2759725T3 (cg-RX-API-DMAC7.html)
MX (1) MX375863B (cg-RX-API-DMAC7.html)
PL (1) PL3221331T3 (cg-RX-API-DMAC7.html)
PT (1) PT3221331T (cg-RX-API-DMAC7.html)
TW (1) TWI690536B (cg-RX-API-DMAC7.html)
WO (1) WO2016079517A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3221333T3 (da) 2014-11-19 2019-09-30 Nzp Uk Ltd 6-alfa-alkyl-3,7-dionsteroider som mellemprodukter til fremstilling af steroide FXR-modulatorer
WO2016079520A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
PL3221332T3 (pl) 2014-11-19 2019-10-31 Nzp Uk Ltd Steroidy, 5.beta.-6-alkilo-7-hydroksy-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
CZ2015504A3 (cs) * 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
CA3009149A1 (en) * 2015-12-22 2017-06-29 Intercept Pharmaceuticals, Inc. Polymorphic crystalline forms of obeticholic acid
GB201608779D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608776D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
WO2018102418A1 (en) * 2016-11-29 2018-06-07 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
EP3431486A1 (en) 2017-07-18 2019-01-23 Bionice, S.L.U. Process and intermediates for the synthesis of obeticholic acid and derivatives thereof
CN111138509B (zh) * 2018-11-02 2022-12-06 东莞东阳光药物研发有限公司 奥贝胆酸的制备方法
CN112521438B (zh) * 2020-12-08 2021-11-23 苏利制药科技江阴有限公司 一种β-谷甾醇的合成工艺
WO2023288123A1 (en) * 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
CN113912661B (zh) * 2021-11-11 2023-04-21 湖南科瑞生物制药股份有限公司 一种7-羟基甾体化合物的合成方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624748A (en) 1950-09-09 1953-01-06 Upjohn Co Bisnorchola-4, 6-dien-3-one-22-al
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
EP0636156B1 (en) 1992-04-14 1997-07-30 Cornell Research Foundation, Inc. Dendritic based macromolecules and method of production
WO1994019366A1 (en) 1993-02-26 1994-09-01 Magainin Pharmaceuticals Inc. Chemical synthesis of squalamine
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
ATE303399T1 (de) 2001-03-12 2005-09-15 Intercept Pharmaceuticals Inc Steroide als agonisten für fxr
US20090062256A1 (en) 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
KR100948532B1 (ko) 2001-11-07 2010-03-23 넥타르 테라퓨틱스 분지형 중합체 및 그의 공액체
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007210888A (ja) 2006-01-12 2007-08-23 Mitsubishi Chemicals Corp ステロイド化合物の製造方法
BRPI0707794A2 (pt) 2006-02-14 2011-05-10 Intercept Pharmaceuticals Inc compostos derivados de Ácido biliar, formulaÇÕes e composiÇÕes farmacÊuticas, bem como uso de ditos compostos
ES2523591T3 (es) 2006-06-27 2014-11-27 Intercept Pharmaceuticals Inc. Derivados de ácidos biliares como ligandos de FXR para la prevención o el tratamiento de enfermedades o estados mediados por FXR
WO2008091540A2 (en) 2007-01-19 2008-07-31 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as tgr5 modulators and methods of use thereof
WO2010014836A2 (en) 2008-07-30 2010-02-04 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
US8999964B2 (en) 2008-11-19 2015-04-07 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
DK2376519T3 (da) 2008-11-19 2014-02-03 Intercept Pharmaceuticals Inc TGR5-modulatorer og fremgangsmåde til anvendelse deraf
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
EA201990211A1 (ru) 2012-06-19 2019-06-28 Интерсепт Фармасьютикалз, Инк. Получение, применение и твердые формы обетихолевой кислоты
MX361653B (es) 2012-10-26 2018-12-13 Intercept Pharmaceuticals Inc Procedimiento para la preparación de derivados del ácido biliar.
KR102106186B1 (ko) 2012-11-28 2020-05-04 인터셉트 파마슈티컬즈, 인크. 폐 질환의 치료
US20140206657A1 (en) * 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
ES2847002T3 (es) 2013-05-14 2021-07-30 Intercept Pharmaceuticals Inc Derivados 11-hidroxil-6-sustituidos de ácidos biliares y conjugados de aminoácido de los mismos como moduladores del receptor X farnesoide
CN105392780A (zh) 2013-05-24 2016-03-09 雀巢产品技术援助有限公司 用于预测肠易激综合征诊断的途径特异性测定
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
RS64050B1 (sr) 2014-05-29 2023-04-28 Bar Pharmaceuticals S R L Derivati holana za upotrebu u lečenju i/ili prevenciji fxr i tgr5/gpbar1 posredovanih bolesti
KR20170094184A (ko) 2014-11-06 2017-08-17 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
PL3221332T3 (pl) 2014-11-19 2019-10-31 Nzp Uk Ltd Steroidy, 5.beta.-6-alkilo-7-hydroksy-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
DK3221333T3 (da) 2014-11-19 2019-09-30 Nzp Uk Ltd 6-alfa-alkyl-3,7-dionsteroider som mellemprodukter til fremstilling af steroide FXR-modulatorer
WO2016079520A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
KR20170099909A (ko) 2014-11-26 2017-09-01 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
CN106279328A (zh) 2015-05-20 2017-01-04 重庆药友制药有限责任公司 一种制备6α-烷基鹅去氧胆酸的方法
EP3310801B1 (en) 2015-06-19 2021-04-07 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
CN106397522A (zh) 2015-07-31 2017-02-15 中国人民解放军军事医学科学院毒物药物研究所 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN106478756A (zh) 2015-09-02 2017-03-08 中美华世通生物医药科技（武汉）有限公司 Oca-e单晶及其制备方法和用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
EA033427B1 (ru) 2019-10-31
KR20170086604A (ko) 2017-07-26
US10301350B2 (en) 2019-05-28
BR112017010319A2 (pt) 2017-12-26
US20170327528A1 (en) 2017-11-16
CN107207559A (zh) 2017-09-26
EP3221331A1 (en) 2017-09-27
JP2017534670A (ja) 2017-11-24
MX375863B (es) 2025-03-07
NZ731924A (en) 2020-12-18
HK1246801A1 (en) 2018-09-14
CN107207559B (zh) 2019-10-25
KR102526631B1 (ko) 2023-04-27
PL3221331T3 (pl) 2020-03-31
TW201632537A (zh) 2016-09-16
DK3221331T3 (da) 2019-12-02
BR112017010319B1 (pt) 2023-04-11
WO2016079517A1 (en) 2016-05-26
EA201790884A1 (ru) 2017-11-30
MX2017006563A (es) 2018-01-26
EP3221331B1 (en) 2019-09-18
EA201790884A8 (ru) 2019-07-31
JP6700274B2 (ja) 2020-05-27
PT3221331T (pt) 2019-12-23
TWI690536B (zh) 2020-04-11
CA2968309A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
ES2759725T3 (es) Esteroides 6-alquil-7-hidroxi-4-en-3-ona como intermediarios para la producción de moduladores de FXR esteroideo
ES2748692T3 (es) Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la producción de moduladores FXR de esteroides
ES2733643T3 (es) Esteroides 5.beta.-6-alquil-7-hidroxi-3-ona como intermedios para la producción de moduladores FXR de esteroides
ES2878577T3 (es) Intermedios para la síntesis de derivados del ácido biliar, en particular del ácido obeticólico
HK1244285A1 (en) 5.beta -6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
ES2857869T3 (es) 6,7-beta-epóxidos de esteroides como compuestos intermedios químicos
EP3221334A1 (en) 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
HK1246801B (en) 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
HK1244287B (en) 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
NZ731924B2 (en) 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
HK1244286B (en) 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators